ETNB Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
89bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.98 |
| 52 Week High | US$16.63 |
| 52 Week Low | US$6.43 |
| Beta | 1.03 |
| 1 Month Change | -8.59% |
| 3 Month Change | 10.99% |
| 1 Year Change | -29.94% |
| 3 Year Change | -37.12% |
| 5 Year Change | -68.85% |
| Change since IPO | -61.63% |
Recent News & Updates
89bio: Surviving A Competitive Space - For Now
Oct 29Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?
Sep 26
89bio: Bullish In Light Of Further MOA Being Established By Peer
Aug 07Recent updates
89bio: Surviving A Competitive Space - For Now
Oct 29Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?
Sep 2689bio: Bullish In Light Of Further MOA Being Established By Peer
Aug 0789bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy
May 2389bio Still Has A Chance As NASH Race Heats Up
Oct 0689bio completes enrollment in phase 2 trial for NASH treatment
Aug 1889Bio rallies on Deep Track Capital disclosing 10% stake
Jul 0789bio: Undervalued Contender In Race For First NASH Drug Approval
Jul 20We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely
May 0789bio: NASH Drug Developer With Differentiated Profile
Jan 29Shareholder Returns
| ETNB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.4% | -2.3% | -2.6% |
| 1Y | -29.9% | -6.3% | 24.5% |
Return vs Industry: ETNB underperformed the US Biotechs industry which returned -6.3% over the past year.
Return vs Market: ETNB underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| ETNB volatility | |
|---|---|
| ETNB Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ETNB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ETNB's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 70 | Rohan Palekar | www.89bio.com |
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
89bio, Inc. Fundamentals Summary
| ETNB fundamental statistics | |
|---|---|
| Market cap | US$919.49m |
| Earnings (TTM) | -US$288.96m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.2x
P/E RatioIs ETNB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ETNB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$288.96m |
| Earnings | -US$288.96m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.46 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 9.4% |
How did ETNB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 02:42 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
89bio, Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Geoffrey Meacham | BofA Global Research |
| Kristen Kluska | Cantor Fitzgerald & Co. |